News Column

New Findings from C.Q. Mao and Co-Authors Describe Advances in Small Interference RNAs (siRNAs)

June 4, 2014



By a News Reporter-Staff News Editor at Biotech Week -- Current study results on Small Interference RNAs (siRNAs) have been published. According to news reporting out of Jiangsu, People's Republic of China, by NewsRx editors, research stated, "The KRAS mutation is present in similar to 20% of lung cancers and has not yet been effectively targeted for therapy. This mutation is associated with a poor prognosis in non-small-cell lung carcinomas (NSCLCs) and confers resistance to standard anticancer treatment drugs, including epidermal growth factor receptor tyrosine kinase inhibitors."

Our news journalists obtained a quote from the research, "In this study, we exploited a new therapeutic strategy based on the synthetic lethal interaction between cyclin-dependent kinase 4 (CDK4) downregulation and the KRAS mutation to deliver micellar nanoparticles (MNPs) containing small interfering RNA targeting CDK4 (MNPsiCDK4) for treatment in NSCLCs harboring the oncogenic KRAS mutation. Following MNPsiCDK4 administration, CDK4 expression was decreased, accompanied by inhibited cell proliferation, specifically in KRAS mutant NSCLCs. However, this intervention was harmless to normal KRAS wild-type cells, confirming the proposed mechanism of synthetic lethality."

According to the news editors, the research concluded: "Moreover, systemic delivery of MNPsicDK4 significantly inhibited tumor growth in an A549 NSCLC xenog raft murine model, with depressed expression of CDK4 and mutational KRAS status, suggesting the therapeutic promise of MNPsiCDK4 delivery in KRAS mutant NSCLCs via a synthetic lethal interaction between KRAS and CDK4."

For more information on this research see: Synthetic Lethal Therapy for KRAS Mutant Non-small-cell Lung Carcinoma with Nanoparticle-mediated CDK4 siRNA Delivery. Molecular Therapy, 2014;22(5):964-973. Molecular Therapy can be contacted at: Nature Publishing Group, 75 Varick St, 9TH Flr, New York, NY 10013-1917, USA. (Elsevier - www.elsevier.com; Molecular Therapy - www.elsevier.com/wps/product/cws_home/622922)

Our news journalists report that additional information may be obtained by contacting C.Q. Mao, Suzhou GenePharma, Suzhou, Jiangsu, People's Republic of China. Additional authors for this research include M.H. Xiong, Y. Liu, S. Shen, X.J. Du, X.Z. Yang, S. Dou, P.Z. Zhang and J. Wang (see also Small Interference RNAs (siRNAs)).

Keywords for this news article include: Asia, Jiangsu, Therapy, Genetics, Oncology, Lung Diseases, Lung Neoplasms, Bronchial Neoplasms, Small Cell Carcinoma, Bronchogenic Carcinoma, Small Cell Lung Cancer, People's Republic of China, Non-Small-Cell Lung Cancer, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Small Interference RNAs (siRNAs)

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Biotech Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters